Although cancer metastasis is associated with poor prognosis, the mechanisms of this event, especially via lymphatic vessels, remain unclear. Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) is expressed on lymphatic vessel endothelium and is considered to be a specific marker of lymphatic vessels, but it is unknown how LYVE-1 is involved in the growth and metastasis of cancer cells. We --
| INTRODUCTION
Cancer metastasis is associated with poor prognosis and accounts for the majority of cancer-related deaths. [1] [2] [3] There are 2 major mechanisms by which cancer metastasis occurs: hematogenous and lymphogenous metastasis. 4, 5 The lymphatic route has been shown to be more important as an initial route for the spread of cancer than the hematogenous route, 6, 7 especially for carcinomas (epithelial cancers).
Accordingly, metastatic spread to lymph nodes (LN) is regarded as a prognostic indicator, 8 but the details of the mechanism of lymphogenous metastasis are unclear.
Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) is a homolog of cluster of differentiation (CD) 44, a receptor for hyaluronan expressed on lymphatic endothelial cells (LEC), 9, 10 and is utilized as a lymphatic-specific marker. LYVE-1 binds to hyaluronan, and is involved in the migration of LEC, 11, 12 as well as in the transport of hyaluronan to the liver and regional LN. 13 Furthermore, LYVE-1 promotes hyaluronaninduced lymphangiogenesis. 11, 14 In clinical studies, LYVE-1 proteins were significantly increased in colon tumors compared with in unaffected colon tissues. 15 LYVE-1 gene expression was upregulated in muscle-invasive bladder cancers exhibiting positive lympho-vascular invasion and LN metastasis compared with in non-muscle invasive bladder cancers. 16 In a xenograft mouse model, intratumoral and peritumoral LYVE-1-positive vessels increased in vascular endothelial growth factor (VEGF)-C-overexpressing breast cancer cells. 17, 18 These findings suggest that LYVE-1 is a potential target for cancer therapy, but it is not known whether cancer therapy targeting LYVE-1 can improve primary cancer formation, tumor progression or cancer metastasis.
In this study, we produced novel anti-mouse LYVE-1 rat monoclonal antibodies (mAb), and found them to be useful tools for the treatment of human cancers.
| MATERIALS AND METHODS

| Animals
Female F344/N rats, male BALB/c mice, and male KSN nude mice were purchased from Shimizu Animal Farm (Kyoto, Japan), and male SCID mice were purchased from Japan SLC (Hamamatsu, Japan) at 6 weeks of age. All animals were maintained in specific pathogen-free conditions. They were housed individually in plastic cages under a standard light/dark cycle (12-hout light cycle starting at 07:00 hours)
at a constant temperature of 23 ± 1°C, and had ad libitum access to food and water. All animal experiments in the present study were approved by the Committee for the Care and Use of Laboratory Animals at Kindai University (KAPS-23-004, KAPS-26-019 and KAPS-27-006), and performed following the institutional guidelines.
| Transfectants expressing LYVE-1
Mouse LYVE-1 cDNA was reverse transcribed with a First Strand cDNA Synthesis kit (GE Healthcare, Chicago, IL, USA) from total RNA prepared by Isogen II (Nippon Gene, Toyama, Japan) of mouse stomach tissues rich in lymphatic vessels. Green fluorescent protein (GFP) was fused to the carboxy terminus of full-length (membrane form) or the extracellular domain (secretory form) of mouse LYVE-1 in the pAcGFP vector (BD Biosciences, Mountain View, CA, USA).
Transfection of the full-length or secretory mouse LYVE-1-GFP vector into cells was performed using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.
Cells were selected using culture media containing 400 μg/mL G418 (Nacalai Tesque, Kyoto, Japan), and were sorted by cellular green fluorescence using a JSAN cell sorter (Bay Bioscience, Kobe, Japan). 
| Production of rat mAb against mouse LYVE-1
Production of anti-LYVE-1 mAb was carried out according to our previous reports. 20 
| Enzyme-linked immunosorbent assay
Soluble mouse LYVE-1 fused to GFP or soluble mouse CD44 23, 24 fused to GFP was adsorbed to the wells in polyvinyl chloride 96-well
plates (E-type, Sumitomo Bakelite, Tokyo, Japan) overnight at 4°C.
Each well was treated with Block Ace (Dainihon Seiyaku, Osaka, Japan)
for 1 hour at 37°C, and then hybridoma culture supernatants (undiluted) or purified antibody (38M or 64R: 10 μg/mL) were added to each well. One hour after the incubation at room temperature (RT), Based on the mean fluorescence intensity (MFI) with or without primary mAb, the subtracted (Δ) MFI or the ratio (+mAb/−mAb) of MFI (rMFI) was calculated. On competitive binding inhibition, the % binding inhibition was calculated using the MFI of PE-labeled 38M or 64R with or without excess unlabeled mAb.
| Isolation of primary LEC and FCM
The LEC isolation was performed as previously reported. 
| Immunoperoxidase staining of mouse tissues
Mice were anesthetized with isoflurane (Wako) and each organ was was observed using a Zeiss Axiolab microscope (Carl Zeiss, Oberkochen, Germany).
| Confocal analysis of mouse tissues
Mouse tissue sections prepared as described in the previous section 
| Wound healing assay
The HEK293F cells expressing mouse LYVE-1-GFP or SVEC4-10 cells were plated onto plastic dishes. When the cells neared 100%
confluency, scratch wounds were made by scraping the cell layer with a micropipette tip. Supernatants from MDA-231 cells were then added to the wounded cultures with or without anti-LYVE-1 mAb.
Images of each scratch wound were taken using a Zeiss Axiolab microscope (Carl Zeiss).
| In vitro tube formation assay
The tube formation assay was performed as previously reported. 14, 27 Matrigel (Corning, Corning, NY, USA) was added to each well 
| RESULTS
| Production of rat mAb against mouse LYVE-1
Expression plasmids encoding cDNA of GFP-fused mouse LYVE-1 (GFP-LYVE-1) were transfected into RH7777 rat hepatoma cells, and stable transfectant clones were established by G418-selection and cell sorting. Rats were immunized with these transfectant clones 4
times, and splenocytes obtained from the immunized rats were fused with mouse myeloma cells. As the first screening, we examined the reactivity of the antibodies in the supernatants of hybridomas with the GFP-fused soluble extracellular domain of mouse LYVE-1 on ELISA, and then selected 64 hybridoma cell lines that secreted anti-LYVE-1 mAb ( Figure 1A ). Next, we evaluated the specificity of the anti-LYVE-1 mAb that we selected in the first screening on the second screening with FCM. Two mAb, designated 38M (IgG 2a /κ) and 64R (IgG 2a /κ), strongly reacted with LYVE-1-expressing RH7777 and HEK293F cells in a GFP expression level-dependent manner (Figure 1B) . Furthermore, these mAb did not bind to the secretory form of mouse CD44 hyaluronan receptor, which is functionally and structurally related to LYVE-1 ( Figure 1C ). On immunoprecipitation analysis, both 38M and 64R immunoprecipitated 87-kDa proteins (GFPfused LYVE-1) in extracts prepared from surface-biotinylated GFP-LYVE-1-expressing HEK293F cells ( Figure 1D ).
We then examined whether 38M and 64R recognize the same epitope using a competitive binding inhibition assay on FCM (Figure 2 ).
The reactivity of PE-labeled 38M against HEK293 cells expressing mouse LYVE-1 was significantly reduced with excess unlabeled 38M
(88.5% binding inhibition) but not with 64R (9.3%), and that of PElabeled 64R was reduced with unlabeled 64R (93.1%) but not with 38M (7.7%; Figure 2 ), demonstrating that each mAb recognizes a different epitope on the extracellular domain of mouse LYVE-1.
We analyzed the effects of cell fixation on the reactivity of anti-LYVE-1 mAb. Although both 38M and 64R mAb retained reactivity with HEK293F cells expressing mouse LYVE-1 after treatment with 4% PFA, the MFI decreased to 72.8% (38M) and 52.4% (64R) of that of unfixed living cells (100%), indicating that the epitope recognized by 64R is more sensitive to PFA fixation than that recognized by 38M (data not shown).
We next evaluated the reactivity of our mAb with primary mouse LEC ( Figure 3A ) and the SVEC4-10 LEC line ( Figure 3B-D) .
Anti-LYVE-1 rabbit pAb reacted with approximately one-fourth of the CD45 − non-hematopoietic cells isolated from mouse LN. 38M
and 64R also reacted with 29% (38M) and 17% (64R) of DAPIunstained and CD45 − viable non-hematopoietic cells, respectively.
The SVEC4-10 mouse LEC cells were definitely reactive with 38M, 64R, and anti-LYVE-1 rabbit pAb, but faintly with anti-CD31 rabbit pAb ( Figure 3B ,C). All 38M + and 64R + cell populations were detected in SVEC4-10 cells stained with anti-LYVE-1 rabbit pAb ( Figure 3D ).
| Expression of LYVE-1 in lymphatic vessels of various mouse tissues
Given that LYVE-1 is expressed on endothelial cells of lymphatic vessels, we immunostained the axillary LN in mice with 38M and 64R. On immunohistochemical analysis, 38M and 64R stained lymphatic vessels ( Figure 4A ). Given that the immunostaining signals of 38M were stronger than those of 64R ( Figure 4A ), we next examined the reactivity of 38M in different tissues, such as gastrointestinal (esophagus, stomach, cecum), respiratory (lung, trachea), cardiovascular (heart), muscle (tongue), skin (ear), and lymphoid (nose) tissues, and found that 38M reacted with lymphatic vessels in all tested mouse tissues ( Figure 4B ). 64R rat mAb. B, SVEC4-10 LEC were analyzed for reactivity with 38M and 64R. C, SVEC4-10 LEC were analyzed for reactivity with pAb. D, SVEC4-10 cells were stained with a combination of αLYVE-1 rabbit pAb and 38M or 64R. PE, phycoerythrin
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| Expression of LYVE-1 on the surface of lymphatic vessels but not blood vessels
To confirm LYVE-1 as a specific marker of lymphatic vessels, we compared the localization of CD31 and LYVE-1 in mouse stomach tissue from which mouse LYVE-1 cDNA was obtained ( Figure 5 ). First, we examined the co-localization of LYVE-1 stained with 38M anti-mouse LYVE-1 rat mAb and the antimouse LYVE-1 rabbit pAb available on the market. Based on 2-color immunostaining followed by confocal analysis, the components stained with both antibodies were completely matched and merged on the endothelia of lymphatic vessels, confirming the specificity of our rat mAb ( Figure 5, upper panels) . Next, we performed 2-color immunostaining of mouse stomach tissues with 38M and rabbit pAb recognizing mouse CD31, which is a specific marker of blood vessels. On confocal microscopy analysis, the components stained with both antibodies were completely separated, demonstrating the reactivity of 38M mAb against LYVE-1 to be a specific marker of lymphatic vessels ( Figure 5 , lower panels).
| Effects of anti-LYVE-1 mAb on the migration of LYVE-1-positive cells
Lymphangiogenesis is associated with cancer metastasis, 29 Figure 7B ). In contrast, although the bioluminescence intensity in the primary tumor decreased by half, it was not significant ( Figure 7B ).
| Effects of anti-LYVE-1 mAb on primary tumor growth in vivo
We next evaluated whether the purified anti-LYVE-1 mAb were able to inhibit tumor growth of the primary lesion. The 64R mAb significantly suppressed tumor growth by MDA-231 cells compared with control rat IgG ( Figure 7C ). Furthermore, we found that the anti-LYVE-1 mAb decreased the amount of lymphatic vessels in the tumor lesion derived from MDA-231 cells as compared with that in control mice ( Figure 7D ).
| DISCUSSION
Although the metastasis of cancer cells leads to poor prognosis, little is known about its mechanisms. Between the 2 different patterns of metastasis, the lymphatic route is considered to play a more critical role than the hematogenous route, especially in human carcinomas. 6, 7 Therefore, it is important to clarify the mechanism of lymphogenous metastasis to discover novel inhibitors of cancer metastasis. LYVE-1 is specifically expressed in lymphatic vessels, 9, 10 but it is unclear whether LYVE-1 is involved in cancer metastasis. In this study, we examined whether LYVE-1 is involved in cancer metastasis and assessed its suitability as a target for cancer therapy.
Prior to this study, we used FCM to select mAb reacting with transfectants expressing GFP-fused target molecules in a GFPexpression-dependent manner as the first screening, 20, 21 but this method was difficult for rapid and simultaneous screening of a large number of antibody samples. Given that LYVE-1 is a type 1 singlepass membrane protein, secreted (soluble) proteins can be prepared, as in the case for HER4. 22 We adopted ELISA as the first screening with soluble LYVE-1 proteins, which has a higher throughput than FCM, and can efficiently select specific anti-LYVE-1 mAb. The specificity of the mAb was further confirmed via the second screening with FCM. We finally obtained novel anti-LYVE-1 mAb, 38M, and 64R, which bound to transfectants expressing GFP-fused mouse LYVE-1 in a GFP-expression-dependent manner. Furthermore, on ELISA, neither 38M nor 64R reacted with mouse CD44-fused GFP.
Moreover, 38M and 64R were reactive with primary mouse LEC and SVEC4-10 mouse LEC endogenously expressing LIVE-1 proteins.
Taken together, we demonstrated 38M and 64R specifically recognize mouse LYVE-1 proteins.
Although 38M and 64R reacted with lymphatic vessels in mouse tissues ( Figure 4) but not with blood vessels (Figure 5 ), several studies have reported LYVE-1 in CD11b-or F4/80-positive macrophages. 33, 34 38M and 64R, however, did not react with thioglycollate-induced macrophages (data not shown), indicating that the epitopes recognized by 38M and 64R are preferentially expressed on the endothelia of lymphatic vessels.
Ascites fluid containing anti-LYVE-1 mAb inhibited metastasis to axillary LN. Moreover, primary tumor formation was also inhibited, A small peptide derived from somatotropin, which acts as a lymphangiogenesis inhibitor, significantly inhibited the migration of highly metastatic cancer cells. 35 Endostatin was also reported to inhibit cell migration and tumor-induced lymphangiogenesis. 36 Furthermore, CXCL1 secreted from LEC was found to be involved in LEC migration and lymphangiogenesis. 37 Therefore, cell migration is closely related to lymphangiogenesis. In this study, we found that inhibition of LYVE-1 using mAb significantly suppressed in vitro cell Results are expressed as mean ± SEM (n = 3). **P < .01, ***P < .001, vs without mAb. ### P < .001, vs with mAb concentration 2.5 μg/mL. D, Tube formation assay. SVEC4-10 cells were plated onto
Matrigel-coated chambers, and the supernatant from MDA-231 cells was added with or without 64R. Three hours after incubation at 37°C, images were taken using a microscope
In this study, the number of lymphatic vessels in primary tumors was reduced by the anti-LYVE-1 mAb. Given that higher expression of LYVE-1 is observed in LEC during embryogenesis 46 and in initial lymphatic vessels in the early postnatal period, 47 it is possible that LYVE-1 functions in lymphangiogenesis. No difference, however in lymphatic vessel density between LYVE-1 knockout mice and wildtype mice has been reported. 48, 49 This suggests that the role of LYVE-1 in lymphangiogenesis during early development is different from that under pathological conditions. Although further studies are needed to clarify the function of LYVE-1 in lymphangiogenesis in tumor lesions, the difference in the roles of LYVE-1 between pathological and normal conditions may be due to differences in the expression of LYVE-1 and its ligand. In colorectal cancer, LYVE-1 expression and lymphatic vessel density in tumor or normal tissue adjacent to the tumor are significantly higher than in normal tissue. 50 Increased expression of LYVE-1 has also been reported in gastric cancer 51 and in neuroblastoma. 52 Furthermore, increased LYVE-1 protein expression and LYVE-1-positive lymphatic vessel density in intratumor and marginal regions are associated with a poor outcome. 52 Regarding the ligands of LYVE-1, fibroblast growth factor 2 (FGF2) directly binds to LYVE-1 with a higher affinity than hyaluronan, and FGF2 induced LEC proliferation and tube formation via LYVE-1. 53 FGF2 was also increased in numerous tumor tissues. [54] [55] [56] [57] Given that the inhibition of LEC migration by anti-LYVE-1 occurred only in the presence of the MDA-231 cell supernatant in the present study, the anti-LYVE-1 mAb may exhibit anti-lymphangiogenesis effects under pathological conditions such as tumorigenesis.
Several studies have indicated that drugs and molecules with anti-lymphangiogenesis effects suppress tumor growth. A multiple kinase inhibitor, Foretinib, reduced the lymphatic vessel density in tumors and tumor growth in a xenograft mouse model. 58 Furthermore, overexpression of microRNA-128 decreased the number of lymphatic vessels and tumor volume. 59 Here, we demonstrated that the anti-LYVE-1 mAb reduced the tumor volume in vivo. Therefore, these anti-tumor effects are likely due to the reduction of lymphatic vessels in tumor, which inhibits lymphangiogenesis for primary tumor formation. anti-LYVE-1 or isotype control mAb. Results are expressed as mean ± SEM (A,B, n = 4-5; C,D, n = 7). *P < .05, ***P < .001, vs control
In conclusion, anti-LYVE-1 mAb inhibits cancer metastasis and primary tumor formation by suppressing lymphangiogenesis.
Together with the knowledge that primary tumors induce lymphatic vessels to create a specific microenvironment before metastasis, 60 this study strongly suggests that inhibition of lymphangiogenesis by anti-LYVE-1 mAb will play an essential role in cancer therapy. Inhibition of hemangiogenesis by anti-VEGF-A has already been adopted for the therapy of several malignancies. 61, 62 In this context, inhibition of lymphangiogenesis by anti-LYVE-1 mAb may become a next-generation therapy for human cancers. 
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